Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 467 results for "amgen rank"

Amgen (AMGN) Beats Q4 Earnings, Revenue Estimates
Zacks.com

Amgen (AMGN) Robert A. Bradway on Q4 2015 Results - Earnings C...

Operator My name is Jake Long, and I'll be your conference facilitator today for Amgen's fourth quarter 2015 earnings conference call. I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now ... Seeking Alpha, 1 week ago
[x]  
Nasdaq

Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook

Biotech major, Amgen Inc. AMGN, reported fourth quarter 2015 earnings of $2.61 per share, well above the Zacks Consensus Estimate of $2.27 and the year-ago earnings of $2.16. Amgen Inc. (AMGN) Street EPS & Surprise Percent - Last 5 Quarters | ...
 Yahoo! Finance1 week ago
Nasdaq

Amgen's Biosimilar of AbbVie's Humira under FDA Review

Updates on the regulatory front are eagerly awaited by investors in the pharma/biotech sector as they impact the share price of the concerned company. Regulatory updates include events like filing of marketing applications, acceptance of these ...
 Yahoo! Finance2 weeks ago
Nasdaq

Amgen Presents Encouraging Phase III Data on Vectibix

Amgen Inc. AMGN announced detailed results from a phase III study ('0007) on its cancer drug, Vectibix (panitumumab). The global, multicenter, randomized, open-label study (n=377) was conducted to assess the overall survival (OS) benefit of Vectibix ...
 Yahoo! Finance2 weeks ago
Nasdaq

Amgen Kyprolis' Label Expanded, Repatha Approved in Japan

Amgen Inc. AMGN received favorable news with the FDA approving its supplemental new drug application for Kyprolis in combination with dexamethasone or with Celgene Corporation's CELG Revlimid plus dexamethasone for the treatment of patients with ...
 Yahoo! Finance2 weeks ago The biggest winners--and losers--in the 2015 race for new drug approvals  FierceBiotech1 month ago
[x]  
Nasdaq

Biogen's (BIIB) Biosimilar of Amgen's Enbrel Gets EU Nod

Biogen Inc. BIIB announced that its joint venture with Samsung Biologics, Samsung Bioepis, has received marketing authorization for Benepali in the EU. Benepali is a biosimilar version of Amgen Inc.'s AMGN Enbrel (etanercept). Benepali is approved ...
 Yahoo! Finance3 weeks ago
[x]  
Nasdaq

Analyzing Amgen's Dividend Hike

Amgen Inc. ( AMGN ) recently raised its quarterly dividend to $1.00 per share or $4.00 on an annual basis. This way, the stock yields 2.5% if the share price stays at current levels at $158.8. According to GuruFocus, its yield is ranked higher than ...
 Yahoo! Finance1 month ago Amgen Returns More to Shareholders, Hikes Dividend by 27%  Yahoo! Finance1 month ago
Pharmaceutical Business Review

Amgen Regains Rights to Prolia, Xgeva & Vectibix from Glaxo

Amgen Inc. AMGN announced that it has entered into a definitive agreement with GlaxoSmithKline plc GSK. Under this agreement, the former will regain all remaining rights to its bone drugs Prolia and Xgeva as well as cancer drug Vectibix in 48 ...
 Yahoo! Finance1 month ago Amgen (AMGN) Reclaims Drug Rights from GlaxoSmithKline (GSK) in Plan to Grow Internationally 12/15/2015  ClinicSpace1 month ago Amgen reacquires all product rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitu  CPhI.cn1 month ago Amgen reacquires rights to three drugs from GSK in 48 countries  Pharmaceutical Business Review1 month ago
[x]  
Zacks.com

Amgen's Blincyto and Repatha Positive in Phase III Studies

Amgen Inc. AMGN came up with two important announcements related to its leukemia immunotherapy, Blincyto and PCSK9 inhibitor, Repatha. Blincyto Phase III Study Stopped on Efficacy Amgen announced pre-specified interim analysis from a randomized, ...
 Zacks.com5 days ago
[x]  
Zacks.com

The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis

For Immediate Release Chicago, IL January 08, 2016 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial ...
 Zacks.com1 month ago UBIO: ProShares UltraPro Nasdaq Biotech ETF  Investopedia1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less